Frontline Combination Approaches for Metastatic RCC

Video

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.

Toni Choueiri, MD: For the past year or two and most recently at the Genitourinary Cancers Symposium, we are having an explosion of first-line options in this disease [metastatic renal cell carcinoma]. It is something quite refreshing. The combination of nivolumab and ipilimumab is the only IO [immunotherapy]/IO combination. After multiple cutoffs of the data and follow-up to 4 years, we’re seeing a hazard ratio for survival of 0.6, so stable. This is an option that is illustrated by the NCCN [National Comprehensive Cancer Network] guidelines as a first-line option. Now we are seeing more options coming along. The combination of pembrolizumab and axitinib does have an overall survival after several data cuts, and it is also a preferred regimen, both in [patients with ] favorable and intermediate-poor risk.

The nivolumab and ipilimumab combination is in poor and intermediate only.More recently the option of cabozantinib and nivolumab is also a preferred first-line option in both the favorable and the poor and intermediate, based on the CheckMate 9ER trial. This regimen was approved in January of 2021. There are other recommended regimens, some of them are combinations, some are as a single agent, but these are the most important frontline ones illustrated by the NCCN guidelines.

Transcript edited for clarity.


Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content